Author: Benzinga Newsdesk | August 14, 2025 04:03pm
Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.61) by 26.83 percent. This is a 129.61 percent decrease over earnings of $1.52 per share from the same period last year.